Lensiprazine, formerly known as SLV-314, is a potent in vitro dopamine D(2) receptor antagonist and highly active as serotonin reuptake inhibitor. In vitro and in vivo studies revealed that Lensiprazine has favorable pharmacokinetic properties and a high CNS-plasma ratio. References: Lange JH, Reinders JH, Tolboom JT, Glennon JC, Coolen HK, Kruse CG. Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs. J Med Chem. 2007 Oct 18;50(21):5103-8. Epub 2007 Sep 19. PubMed PMID: 17880057.

纯度：≥98%

CAS：327026-93-7